Autolus Therapeutics Ltd
| Fiscal year | Operating cash flow | Stock comp | Capex | Free cash flow | Net borrowing | FCFE | Shares (B) | FCF per share | Year-end price | FCF yield |
|---|---|---|---|---|---|---|---|---|---|---|
| 2018 | -0.0 | 0.0 | 0.0 | -0.0 | 0.0 | -0.0 | 0.03 | $-1.26 | $32.84 | -3.8% |
| 2019 | -0.1 | 0.0 | 0.0 | -0.2 | 0.0 | -0.2 | 0.04 | $-3.49 | $13.20 | -26.5% |
| 2020 | -0.1 | 0.0 | 0.0 | -0.2 | 0.0 | -0.2 | 0.05 | $-2.96 | $8.94 | -33.1% |
| 2021 | -0.1 | 0.0 | 0.0 | -0.1 | 0.0 | -0.1 | 0.07 | $-1.90 | $5.19 | -36.5% |
| 2022 | -0.1 | 0.0 | 0.0 | -0.1 | 0.0 | -0.1 | 0.09 | $-1.42 | $1.90 | -74.9% |
| 2023 | -0.1 | 0.0 | 0.0 | -0.2 | 0.0 | -0.2 | 0.17 | $-0.96 | $6.44 | -15.0% |
| 2024 | -0.2 | 0.0 | 0.0 | -0.3 | 0.0 | -0.3 | 0.26 | $-1.01 | $2.35 | -42.8% |
| 2025 | -0.3 | 0.0 | 0.0 | -0.3 | 0.0 | -0.3 | 0.27 | $-1.22 | $1.99 | -61.4% |
| 7-yr CAGR | n/m | 16.3% | 17.5% | n/m | n/a | n/m | 35.6% | n/m | -33.0% | avg -36.7% |
| Fiscal year | Revenue | EBITDA | EBITDA margin | Debt incl. leases | Cash & securities | Market cap | Enterprise value | EV / EBITDA | Net debt / EBITDA |
|---|---|---|---|---|---|---|---|---|---|
| 2018 | 0.0 | -0.1 | -5,398.0% | 0.0 | 0.2 | 1 | 1 | n/m | n/m |
| 2019 | 0.0 | -0.2 | -8,355.2% | 0.0 | 0.2 | 1 | 0 | n/m | n/m |
| 2020 | 0.0 | -0.3 | -17,345.5% | 0.1 | 0.2 | 0 | 0 | n/m | n/m |
| 2021 | 0.0 | -0.1 | -8,753.6% | 0.0 | 0.3 | 0 | 0 | n/m | n/m |
| 2022 | 0.0 | -0.1 | -2,187.1% | 0.0 | 0.4 | 0 | -0 | n/m | n/m |
| 2023 | 0.0 | -0.2 | -10,196.5% | 0.1 | 0.2 | 1 | 1 | n/m | n/m |
| 2024 | 0.0 | -0.2 | -2,309.4% | 0.1 | 0.6 | 1 | 0 | n/m | n/m |
| 2025 | 0.1 | -0.3 | -359.5% | 0.1 | 0.3 | 1 | 0 | n/m | n/m |
| 7-yr CAGR | 84.3% | n/m | avg -6,863.1% | n/m | 6.8% | -9.1% | -13.8% | median n/m | avg n/m |
Revenue grew 84.3% a year and EBITDA n/m a year from FY2018 to FY2025, and free cash flow after stock compensation did not grow from a positive base. The share count rose 35.6% a year, so per-share figures grew more slowly than the totals. The balance sheet carried more cash than debt in every one of those years.
From the data: EBITDA was not positive in enough years to set a growth rate and an exit multiple, so there is no hurdle price. The share count moved 36% in FY2019 with no split on record (a merger, offering or buyback), so per-share figures before and after that year are not on one basis. The share count moved 40% in FY2021 with no split on record (a merger, offering or buyback), so per-share figures before and after that year are not on one basis. The share count moved 32% in FY2022 with no split on record (a merger, offering or buyback), so per-share figures before and after that year are not on one basis.
- Free cash flow is operating cash flow less stock-based compensation less capital spending. Stock comp is treated as a real cost.
- Net borrowing is the year's change in long-term debt. FCFE adds it back to free cash flow, the classic one-page definition.
- EBITDA is operating income plus depreciation and amortization. Debt includes lease obligations; cash includes short-term investments.
- Market cap uses the fiscal year-end price as traded, restated for later splits but not for dividends; enterprise value adds debt and subtracts cash.
- Share count is the yearly change in shares outstanding over the period; flat or falling clears. Cash margin is the latest free cash flow margin against its three-year average; within two points clears.
- Hurdle price is the present value, at the hurdle rate, of ten years of modeled free cash flow per share plus a year-10 sale at the exit multiple. It is shown as an exhibit: the 2011 to 2021 back-test found that buying below it did not sort winners from losers, so it is not scored.
- Cleared on a check means the number clears the stated rule; Not cleared means it does not. Durable, Holding and First year say how many fiscal years running the company has cleared all four staying-power checks (four or more, two or three, one); Partial and Not cleared count the checks it clears today. All of it is fact about the filings, not a rating of the stock.